FLT3 and acute myeloid leukemia: Furthermore, the compound lestaurtinib (CEP-701) (568), currently in phase II clinical trials at NCI against relapsed AML and expressing inhibitor of FLT3 among other kinases JAK-2, Trk-A, Trk-B,Trk-C [281].